BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hesperos Inc. - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hesperos Inc.
X-ORIGINAL-URL:https://hesperosinc.com
X-WR-CALDESC:Events for Hesperos Inc.
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260417
DTEND;VALUE=DATE:20260418
DTSTAMP:20260427T184257
CREATED:20260413T172611Z
LAST-MODIFIED:20260413T172611Z
UID:3678-1776384000-1776470399@hesperosinc.com
SUMMARY:Hesperos Presenting at the HNF CMT Summit 2026
DESCRIPTION:Date: 17 April 2026\nTime: 1:50 PM – 2:30 PM (EDT)\nEvent: HNF CMT Summit + Health & Wellness Retreat 2026\nLocation: Ellicott City\, Maryland \nHesperos\, Inc. is proud to announce that our Chief Scientist\, Dr. James J. Hickman\, will be a featured speaker at the upcoming HNF CMT Summit + Health & Wellness Retreat 2026 in Ellicott City\, Maryland. Hosted by the Hereditary Neuropathy Foundation (HNF)\, this event brings together global leaders from academia\, industry\, clinical practice\, and the patient community to explore the latest research and advancements in Charcot-Marie-Tooth (CMT) disease. \nPresentation – Research Track: AI & Technology Advances in CMT \nThe integration of artificial intelligence and microphysiological systems (such as our Human-on-a-Chip® single and multi-organ platform) are becoming a critical bridge for translational success in rare diseases\, including CMT. In this talk\, Dr. Hickman will discuss how these technologies will continue to benefit research and therapeutic development in this and other rare disease arenas. \nHighlights attendees can expect to explore include: \n\nHow artificial intelligence and cutting-edge\, human-relevant in vitro technologies are accelerating drug discovery and target identification for CMT and other rare diseases.\nThe role Hesperos’ serum-free\, multi-organ platforms have played modeling complex neuropathies and supporting therapeutic development\, including an example utilizing sera from an individual patient with CMT2A to evaluate efficacy of a potential therapeutic gaining an Orphan Drug Designation (See March 2025 Announcement).\n\nAbout the Speaker \nJames J. Hickman\, Ph.D.\, is the Chief Scientist and Co-Founder of Hesperos\, Inc. He is also the Founding Director of the NanoScience Technology Center at the University of Central Florida. A pioneer in the field\, Dr. Hickman has spent over 30 years developing functional in vitro systems. He is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE)\, the National Academy of Inventors\, and is the President of the International Microphysiological Systems Society (IMPSS). \nPlanning to attend the CMT Summit 2026? We invite you to connect with Dr. Hickman to discuss how our Human-on-a-Chip® platform technology can support your drug development programs. \nLink to Registration and Full Program \n\n\n 
URL:https://hesperosinc.com/event/cmt-summit-26-invited-talk/
LOCATION:Turf Valley Resort\, 2700 Turf Valley Road\, Ellicott City\, MD\, 21042\, United States
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2026/04/final-mdt-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260408
DTEND;VALUE=DATE:20260409
DTSTAMP:20260427T184257
CREATED:20260403T171458Z
LAST-MODIFIED:20260403T171546Z
UID:3654-1775606400-1775692799@hesperosinc.com
SUMMARY:Hesperos Chief Scientist Presenting at Quantitative Systems Pharmacology Conference 2026​​​​​​​​​​​​​​​​​​
DESCRIPTION:Details:\nDate: 08 April 2026\nTime:  16:10 (UTC+2)\nSession 4: Integrating Micro-Physiological and Organ-on-Chip Systems with QSP \nHesperos\, Inc. is proud to announce that our Chief Scientist\, Dr. James J. Hickman\, will be a featured speaker at the upcoming Quantitative Systems Pharmacology Conference (QSPC) 2026 in Leiden\, Netherlands. This event brings together global leaders from academia\, industry\, and regulatory agencies to explore advances in quantitative systems pharmacology (QSP) and mechanism-based pharmacokinetics and pharmacodynamics (PK/PD).  \nPresentation:\n“Regulatory Acceptance of Microphysiological and Organ-on-Chip Systems”\nAs the drug discovery landscape shifts toward more human-relevant models\, the integration of microphysiological systems (such as our Human-on-a-Chip® single- and multi-organ system models) with QSP is becoming a critical bridge for translational success. In this talk\, Dr. Hickman will discuss the path toward regulatory acceptance for these platforms. \nSession 4 explores the synergy between organ-on-a-chip platforms and the mathematical frameworks of QSP including PK/PD. Among other topics\, attendees will gain a deeper understanding of: \n\nThe current status of MPS validation for regulatory use.\nHow Hesperos’ serum-free\, single and multi-organ platforms can be combined with QSP models.\nStrategies for utilizing human-relevant data to better inform and accelerate clinical development timelines.\n\nAbout the Speaker\nJames J. Hickman\, Ph.D.\, is the Chief Scientist and Co-Founder of Hesperos\, Inc. He is also the Founding Director of the NanoScience Technology Center at the University of Central Florida. A pioneer in the field\, Dr. Hickman has spent over 30 years developing functional in vitro systems. He is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE)\, the National Academy of Inventors\, and is the President of the International Microphysiological Systems Society (IMPSS). \n\nPlanning to attend QSPC 2026? We invite you to connect with Dr. Hickman to discuss how our Human-on-a-Chip® technology can support your drug development programs. \nLink to Registration and Full Program
URL:https://hesperosinc.com/event/hesperos-chief-scientist-presenting-at-quantitative-systems-pharmacology-conference-2026/
LOCATION:Stadsgehoorzaal\, Breestraat 60\, 2311 CS\, Leiden\, Leiden\, Netherlands
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2026/04/JH-Talk-QSPC-2026.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260122
DTEND;VALUE=DATE:20260124
DTSTAMP:20260427T184257
CREATED:20260112T013437Z
LAST-MODIFIED:20260119T182021Z
UID:3463-1769040000-1769212799@hesperosinc.com
SUMMARY:International Conference on Advances in 3D Cell Culture
DESCRIPTION:Invited Speaker\nJames Hickman\, Chief Scientist\, Hesperos Inc. \nPresentation:  Regulatory acceptance of human-on-a-chip systems for efficacy and safety \nJanuary 22-23\, 2026 \nFull Program Agenda\n3DCC26_ProgramAgenda_v2 \nLink to register: https://eventregister.mumbaibiocluster.org/ \n 
URL:https://hesperosinc.com/event/international_conference_advances_3d_cell_culture/
LOCATION:Novotel Dona Sylvia Resort\, Cavelossim Road Mobor\, Cavelossim\, GA\, Goa\, India
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2026/01/1767447014533-e1768846809456.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251205
DTEND;VALUE=DATE:20251206
DTSTAMP:20260427T184257
CREATED:20251107T215334Z
LAST-MODIFIED:20251110T164829Z
UID:3363-1764892800-1764979199@hesperosinc.com
SUMMARY:The 3Rs Collaborative & IQ-Consortium: Microphysiological Systems Webinar & Workshop Series
DESCRIPTION:Webinar: Microphysiological Systems Webinar & Workshop Series\nWednesday\, December 3\, 2025\n10 am-12:30 p.m. (EST)\nInvited Speaker\nJ Hickman\, PhD\, Chief Scientist \n  \nAbout the webinar: 3RsC MPS in Drug Development program is an initiative by The 3Rs Collaborative (3RsC) to advance the adoption and regulatory acceptance of Microphysiological Systems (MPS) technologies\, in alignment with the principles of the 3Rs (Replacement\, Reduction\, and Refinement) in animal research. 
URL:https://hesperosinc.com/event/the-3rs-collaborative-iq-consortium-microphysiological-systems-webinar-workshop-series/
LOCATION:The Three Rs Collaborative\, United States
CATEGORIES:Invited Speaker,Webinar
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2025/11/Na3rc-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250922
DTEND;VALUE=DATE:20250926
DTSTAMP:20260427T184257
CREATED:20250609T154351Z
LAST-MODIFIED:20250610T130827Z
UID:3124-1758499200-1758844799@hesperosinc.com
SUMMARY:23rd Annual Discovery on Target
DESCRIPTION:23rd Annual Discovery on Target\nSept. 22-25 \nInvited Speaker  \nJames Hickman\, PhD\, Hesperos Co-Founder and Chief Scientist \nRegulatory Acceptance of Human-on-a-Chip Platforms \nSept. 22\, 9:00 AM EST \nAbout Discovery on Target: This week long event in Boston\, MA showcases the latest research on current and emerging drug targets and technology.  There will be numerous presentations\, discussions\, and networking opportunities for those at the forefront of drug discovery. \nLearn more and register at https://www.discoveryontarget.com/
URL:https://hesperosinc.com/event/23rd-annual-discovery-on-target/
LOCATION:Sheraton Boston
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2025/06/DOT-banner-LI-standard-speaking-at-code.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20250902T130000
DTEND;TZID=UTC:20250902T143000
DTSTAMP:20260427T184257
CREATED:20250829T195357Z
LAST-MODIFIED:20250829T195357Z
UID:3201-1756818000-1756823400@hesperosinc.com
SUMMARY:WC13 2025: Hesperos CEO Presents "Utilization of human on a chip systems for rare disease regulatory submissions"
DESCRIPTION:Track:  Accelerating rare disease therapeutics via adoption of human biology-based non-clinical drug development in global north and global south countries\nHuman Health – Replacement \nSession Chair \nJanette Turner – Humane World for Animals\n\nSession Speakers \n\nAbstract 553\nUtilization of human on a chip systems for rare disease regulatory submissions\nLawrence Florin\, Hesperos\, Inc.\nAbstract 323\nModelling cardiac arrhythmias with human induced pluripotent stem cells\nAntonio Carvalho\, Federal Univ. Rio de Janeiro\nAbstract 459\nMultiparametric screening of MASH clinical candidates in human liver spheroids predicts clinical outcomes and reveals potential novel combinations for anti-steatotic and anti-fibrotic therapies.\nMadhu Lal-Nag\, https://insphero.com/\nAbstract 464\nAccelerating the development of Complex In Vitro Models (CIVMs) for rare disease therapeutics in India\nFrancesca Pistollato\, Humane World for Animals Europe\n\n\nSession Description\nRare diseases represent a significant disease burden and impact up to 10% of the world’s population. In particular\, south Asian countries experience higher rates of rare genetic disorders which has been attributed to traditional marriage practices of endogamy and consanguinity. Despite this\, there are no approved treatments for almost 95% of rare diseases. While the use of genetically engineered animal models is traditionally considered as one of the main strategies for rare disease therapeutics\, these model systems have often proven unsuitable for providing human-relevant insights into the patho-mechanisms of rare diseases. Recently\, efficacy data from a microphysiological system developed using human cells were used to support the authorisation of a clinical study for chronic inflammatory demyelinating polyneuropathy\, a rare neuromuscular disease. This\, and several other examples\, highlight the potential of complex in vitro models (CIVMs)\, including induced pluripotent stem cell (iPSCs)\, organoids\, and organs-on-chips\, to provide personalized model systems for understanding the biological mechanisms and assessing drug efficacy for rare diseases. \nThis workshop will include two sessions. The first session will aim to provide a global perspective on the status quo of the use and development of complex in vitro models to support drug development of rare diseases. We will hear from experts from around the world who have successfully used CIVMs to demonstrate drug efficacy and learn more about the challenges faced across different global regions. This would include talks on successful case studies that have used CIVMs to test the efficacy of repurposed drugs and progress to clinical trials\, general overview of how industry is currently using these systems in their internal drug development pipeline for rare diseases. The session would also include two talks from global south country-perspective where the higher cost of rare disease treatments also renders it inaccessible to most of the population\, highlighting the need for his would be followed by a session where it would be discussed how these insights from rare diseases could be used to develop a generalised framework for efficacy testing for other disease categories. We hope to develop a white/status paper covering the recommendations that emerge from these sessions. \nSession organization (90 minutes) \nSession 1: Human preclinical models for rare disease therapeutics- Status quo and challenges (45 minutes)\n1. Introduction– How CIVMs can provide a personalized system for efficacy testing\, general statement of needs or challenges (Suggested Speaker: James Hickman\, Hesperos Inc. – we have reached out to Dr Hickman and he has shown interest\, yet to accept)\n2. Case study – Developing efficacy models for cystic fibrosis using lung-on-a-chip (Suggested Speaker: Roberto Plebani\, Emulate. Inc)\n3. Accelerating the development of CIVMs for rare disease therapeutics in India: Not for profit speaker (Suggested speaker: Surat Parvatam\, HSI/India) \nSession 2: Breakout session on developing a generalized framework for incorporating CIVMs for efficacy testing based on insights from rare diseases (45 minutes)\nThis breakout session will focus on discussions on how strategies and insights from efficacy modelling for rare diseases can assist in creating a generalised framework for incorporating CIVMs into efficacy modelling of other disease models.
URL:https://hesperosinc.com/event/wc13-2025-hesperos-ceo-presents-utilization-of-human-on-a-chip-systems-for-rare-disease-regulatory-submissions/
LOCATION:Riocentro Convention Center\, Av. Salvador Allende\, 6555 - Barra Olímpica\, Rio de Janeiro\, Brazil
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2025/08/Screenshot-2025-08-29-135151.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20241204T100000
DTEND;TZID=UTC:20241204T130000
DTSTAMP:20260427T184257
CREATED:20241105T151428Z
LAST-MODIFIED:20241212T170908Z
UID:2806-1733306400-1733317200@hesperosinc.com
SUMMARY:The 3Rs Collaborative Microphysiological Systems Webinar Series: Oncology MPS
DESCRIPTION:The 3Rs Collaborative Microphysiological Systems Webinar Series: Oncology MPS \nInvited Speaker \nJ Hickman\, PhD\, Chief Scientist \nDec. 4th\, 10:00 am – 1:00 pm EST \n“Hesperos will be one of nine companies presenting on oncology MPS.” \nAbout the 3Rs Collaborative MPS Webinar Series:  Beginning December of 2021\, the 3Rs Collaborative (3RsC) and International Consortium for Innovation & Quality (IQ) Microphysiological Systems (MPS) groups worked together to establish a webinar series. This webinar series aims to facilitate communication between MPS stakeholders\, specifically technology providers and end-users.  Webinars are composed of a series of 15-minute long presentations from each company\, followed by a 30 minute long question & answer roundtable.  The 3Rs Collaborative partners with organizations across academia and industry to improve the lives of research animals by promoting the principles of Replacement\, Reduction\, and Refinement. \nRegister free to watch Dr. Hickman’s presentation at https://3rc.org/events/mps-webinars/ \n\n\n\n\n\n\n 
URL:https://hesperosinc.com/event/the-3rs-collaborative-microphysiological-systems-webinar-series-oncology-mps/
LOCATION:Virtual
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/png:https://hesperosinc.com/wp-content/uploads/2024/11/Na3rc-5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241117
DTEND;VALUE=DATE:20241121
DTSTAMP:20260427T184257
CREATED:20241118T154029Z
LAST-MODIFIED:20241212T170917Z
UID:2886-1731801600-1732147199@hesperosinc.com
SUMMARY:60th Interagency Botulism Research Coordinating Committee Meeting (IBRCC)
DESCRIPTION:60th Interagency Botulism Research Coordinating Committee Meeting (IBRCC) \nInvited Speaker \nJ Hickman\, PhD\, Chief Scientist \n“Human neuromuscular junction model for botulinum toxin evaluation for toxicity as well as therapeutic applications” \nNov. 18th\, 4:05 pm EST \n 
URL:https://hesperosinc.com/event/60th-interagency-botulism-research-coordinating-committee-meeting-ibrcc/
LOCATION:Courtyard by Marriott Atlanta Decatur Downtown/Emory
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2024/11/Event-Web-Page-Graphics-19.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241107
DTEND;VALUE=DATE:20241109
DTSTAMP:20260427T184257
CREATED:20241029T143739Z
LAST-MODIFIED:20241105T202224Z
UID:2751-1730937600-1731110399@hesperosinc.com
SUMMARY:Discovery US 2024
DESCRIPTION:Discovery US 2024 \nInvited Speaker \n J Hickman\, Chief Scientist \n“Organ-On-Chip & MPS Systems For Neurodegenerative Diseases” \nNov. 7\, 3:05 PM\, Track 2: Novel Models for ADME-Tox Research & Disease Modelling \nAbout Discovery US:  Discovery US supports the discovery of novel therapeutics by brining together experts in target discovery and validation from across small & large biopharma organizations to discuss how the newest therapeutic paradigms can overcome historic challenges in drug development and provide optimized\, novel drug candidates.  Sessions will showcase key platforms and new technologies impacting early drug pipelines.  This year’s meeting will be in Boston\, MA\, Nov 7-8th. \nLearn more and register at https://oxfordglobal.com/discovery-development/events/discovery-us-2024# \nWe hope to see you there!
URL:https://hesperosinc.com/event/discovery-us-congress-by-oxford-bio/
LOCATION:MD
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/png:https://hesperosinc.com/wp-content/uploads/2024/10/Event-Web-Page-Graphics-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240918
DTEND;VALUE=DATE:20240919
DTSTAMP:20260427T184257
CREATED:20241029T145931Z
LAST-MODIFIED:20241105T152745Z
UID:2764-1726617600-1726703999@hesperosinc.com
SUMMARY:Labroots Cell Biology Virtual Event Series
DESCRIPTION:Labroots Cell Biology Virtual Events Series \nInvited Speaker \nJ Hickman\, PhD\, Chief Scientist \n“Human-On-a-Chip for Therapeutic Index & Toxicity” \nSept. 18th\, on demand all day \nAbout the Labroots Cell Biology Virtual Event Series:  This virtual event provides a place for interdisciplinary exchange and knowledge-sharing opportunities.  Leading experts\, researchers\, and innovators will share breakthroughs and discuss the latest trends and methodologies in cell biology. \nRegister free to watch Dr. Hickman’s presentation at https://www.labroots.com/virtual-event/cell-biology-2024
URL:https://hesperosinc.com/event/past-event-test/
LOCATION:Virtual
CATEGORIES:Invited Speaker
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2024/10/Event-Web-Page-Graphics-11.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240610
DTEND;VALUE=DATE:20240615
DTSTAMP:20260427T184257
CREATED:20241105T151402Z
LAST-MODIFIED:20241105T152717Z
UID:2854-1717977600-1718409599@hesperosinc.com
SUMMARY:MPS World Summit 2024
DESCRIPTION:MPS World Summit 2024 \nInvited Speaker \nJ. Hickman\, PhD\, Chief Scientist \n“Human-on-a-chip systems for use in neurological disease and aging research“ \nJune 11\, 2:30pm\, 320-322 \n  \nHesperos Presentations \nAkhmetzada Kargazhanov:  “Evaluating the neuromuscular pathology in Alzheimer’s disease from familial mutations by utilizing a human iPSC-derived in vitro functional NMJ model” \nJune 10\, 11:15 am\, 327 \nWilliam Bogen: “Design and implementation of a custom machine learning model for segmentation of electrophysiological cardiomyocyte responses in organ-on-a-chip applications” \nJune 12 3:40 pm\, 320-322 \nWalker Hagan\, PhD: “A Human-on-a-Chip® CMT2S model for the evaluation of personalized medicine” \nJune 12\, 4:00 pm\, 323-325 \nAakash Patel: “A multi-organ human-on-a-chip system modeling chronic opioid overdose rescue efficacy and off-target toxicity” \n June 13\, 1:00 pm\, Flex A \nMichael Jakob Rupar: “Implementation of a Human Cell-Based Malaria-on-a-Chip Phenotypic Disease Model for Drug Efficacy Evaluation” \nJune 14\, 12:10 pm\, 327-329 \nDallas Nash: “Investigation into the effect of APOE4 iPSC derived astrocytes on the blood brain barrier through in vitro models” \nJune 14\, 12:20 pm\, 320-322 \n  \nHesperos at MPS World Summit 2024 \nVisit us at Booth #3 in Summit Building Flex C! \n  \nHesperos Posters \nXiufang Guo\, PhD: #436 \nJune 11\, 10-11:30 am \nKenneth Hawkins: #562 \n June 11\, 10-11:30 am \nKaveena Autar\, PhD:#168 \nJune 11\, 4:30-6 pm \nMaria Grisales: #338 \nJune 11\, 4:30-6 pm \nZhanhe Liu\, PhD: #468 \nJune 11\, 4:30-6 pm \nJoseph Ciurca: #469 \nJune 12\, 10-11:30 am \nAakash Patel: #360  \nJune 13\, 10-11:30 am \nGabriel Kaatz: #589 \n June 13\, 4:30-6 pm \nAkhmetzada Kargzhanov: #653 \nJune 13\, 4:30-6 pm \nMridu Malik\, PhD: #502 \nJune 13\, 4:30-6 pm \nAbout MPS World Summit 2024: MPS World Summit is a gathering organized by the International Microphysiological Systems Society (IMPSS) for leaders in the MPS field to present the latest scientific achievements\, discuss the advances and challenges\, and educate young and newly interested scientists.  The 2024 Summit is the 4th annual MPS World Summit and will take place in Seattle\, WA. \nLearn more and register at https://mpsworldsummit.org/
URL:https://hesperosinc.com/event/mps-world-summit-2024/
LOCATION:Seattle Convention Center\, Seattle\, WA\, United States
CATEGORIES:Exhibitor,Invited Speaker,Poster Presentation
ATTACH;FMTTYPE=image/jpeg:https://hesperosinc.com/wp-content/uploads/2024/11/Event-Web-Page-Graphics-10.jpg
END:VEVENT
END:VCALENDAR